The protective effects of ligustrazine on ischemia-reperfusion and DPPH free radical-induced myocardial injury in isolated rat hearts.
Previous investigations have suggested that tumor necrosis factor-alpha (TNF-alpha) can contribute to myocardial damage during ischemia-reperfusion. In the present study, we examined whether the cardioprotective effects of ligustrazine are related to inhibition of TNF-alpha production in the rat models of ischemia-reperfusion and 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical-induced myocardial injury. Ischemia for 20 min and reperfusion for 40 min caused a decline in cardiac function (left ventricular pressure, +/- d p/d t(max), heart rate and coronary flow) and an increase in the release of creatine kinase in coronary effluent and the content of TNF-alpha in myocardial tissues. Similarly, perfusion with DPPH (100 nM) for 30 min significantly decreased cardiac function, and increased the release of creatine kinase and the content of TNF-alpha. Ligustrazine at the concentration of 40 or 80 mg/L markedly improved cardiac function and reduced the release of creatine kinase and the content of TNF-alpha in myocardial tissues in hearts subjected to ischemia-reperfusion or DPPH perfusion. These results suggest that the cardioprotection afforded by ligustrazine is related to a reduction of TNF-alpha content by inhibition of free radical production in isolated rat hearts.
Zhou
Yuan
Y
Department of Pharmacology, Medical College, Hunan Normal University, Changsha, Hunan, P. R. China.
Hu
Chang-Ping
CP
Deng
Pan-Yue
PY
Deng
Han-Wu
HW
Li
Yuan-Jian
YJ
D000818:Animals; D001713:Biphenyl Compounds; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D030004:Ligusticum; D008297:Male; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D008517:Phytotherapy; D010851:Picrates; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D001713:Biphenyl Compounds; D002316:Cardiotonic Agents; D010851:Picrates; D010936:Plant Extracts; D011719:Pyrazines; D014409:Tumor Necrosis Factor-alpha; C004931:1,1-diphenyl-2-picrylhydrazyl; C017953:tetramethylpyrazine